Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States.
The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema.
The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial.
In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development.
The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 21, 24 | -0.66 Increased by +25.00% | -0.74 Increased by +10.81% |
| Feb 29, 24 | -0.75 Increased by +10.71% | -0.74 Decreased by -1.35% |
| Nov 9, 23 | -0.24 Increased by +69.62% | -0.59 Increased by +59.32% |
| Aug 9, 23 | -0.77 Increased by +11.49% | -0.81 Increased by +4.94% |
| May 10, 23 | -0.88 Decreased by -7.32% | -0.89 Increased by +1.12% |
| Mar 15, 23 | -0.84 Increased by +1.18% | -0.79 Decreased by -6.33% |
| Nov 8, 22 | -0.79 Increased by +3.66% | -0.91 Increased by +13.19% |
| Aug 11, 22 | -0.87 Decreased by -210.71% | -0.85 Decreased by -2.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 28.00 K Decreased by -90.60% | -32.40 M Decreased by -18.87% | Decreased by -115.72 K% Decreased by -1.17 K% |
| Dec 31, 23 | -19.00 K Decreased by -101.52% | -32.28 M Decreased by -18.37% | Increased by +169.91 K% Increased by +7.87 K% |
| Sep 30, 23 | 20.20 M Increased by +3.94 K% | -10.26 M Increased by +57.43% | Decreased by -50.76% Increased by +98.95% |
| Jun 30, 23 | 239.00 K Increased by +47.53% | -29.62 M Decreased by -8.06% | Decreased by -12.39 K% Increased by +26.75% |
| Mar 31, 23 | 298.00 K Decreased by -75.55% | -27.26 M Decreased by -4.10% | Decreased by -9.15 K% Decreased by -325.84% |
| Dec 31, 22 | 1.25 M Increased by +1.26 K% | -27.27 M Decreased by -8.73% | Decreased by -2.19 K% Increased by +91.98% |
| Sep 30, 22 | 500.00 K Decreased by -63.40% | -24.09 M Decreased by -8.33% | Decreased by -4.82 K% Decreased by -195.96% |
| Jun 30, 22 | 162.00 K Decreased by -98.89% | -27.41 M Decreased by -261.13% | Decreased by -16.92 K% Decreased by -32.40 K% |